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PURPOSE. In the eye, chronic hypoxia/reoxygenation (H/R) contributes to the development of
a number of ocular disorders. H/R induces the production of reactive oxygen species (ROS),
leading to poly(ADP-ribose) polymerase-1 (PARP1) activation that promotes inflammation,
cell death, and disease progression. Here, we analyzed the protective effects of the PARP1
inhibitor olaparib in H/R-induced retina injury and investigated the signaling mechanisms
involved.
METHODS. A rat retinal H/R model was used to detect histologic and biochemical changes in
the retina.
RESULTS. H/R induced reductions in the thickness of most retinal layers, which were
prevented by olaparib. Furthermore, H/R caused increased levels of Akt and glycogen
synthase kinase-3b phosphorylation, which were further increased by olaparib, contrib-
uting to retina protection. By contrast, H/R-induced c-Jun N-terminal kinase and p38
mitogen-activated protein kinases (MAPK) phosphorylation and activation were reduced
by olaparib, via mitogen-activated protein kinase phosphatase 1 (MKP-1) expression. In
addition, H/R-induced hypoxia-inducible factor 1a (HIF1a) levels were decreased by
olaparib, which possibly contributed to reduced VEGF expression. Nuclear factor
(erythroid-derived 2)-like 2 (Nrf2) expression was slightly increased by H/R and was
further activated by olaparib. Nuclear factor-jB (NFjB) was also activated by H/R through
phosphorylation (Ser536) and acetylation (Lys310) of the p65 subunit, although this was
significantly reduced by olaparib.
CONCLUSIONS. Olaparib reduced H/R-induced degenerative changes in retinal morphology. The
protective mechanisms of olaparib most probably involved Nrf2 activation and ROS
reduction, as well as normalization of HIF1a and related VEGF expression. In addition,
olaparib reduced inflammation by NFjB dephosphorylation/inactivation, possibly via the
PARP1 inhibition–MKP-1 activation–p38 MAPK inhibition pathway. PARP inhibitors represent
potential therapeutics in H/R-induced retinal disease.
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Retinal ischemia–reperfusion injury occurs in several eyediseases, among them probably glaucoma, diabetic reti-
nopathy, and other ocular vascular disorders1–3 are the most
important. Reactive oxygen species (ROS) production in retinal
ischemia–reperfusion injury leads to lipid oxidation, protein
disorder, and DNA damage.4,5 Ischemic injury leads to oxidative
stress initiating mitochondrial damage, which can activate cell
death pathways.6–8 ROS and peroxynitrite can initiate DNA
breaks followed by activation of poly(ADP-ribose) polymerase-1
(PARP1), a nuclear enzyme involved in DNA repair.9 PARP1
catalyzes PARylation of nuclear proteins that leads to alteration
of signaling pathways and transcription factors.10 PARP
activation suppresses protein kinase B (Akt) activation11 and
activates c-Jun N-terminal kinase (JNK) and p38 mitogen-
activated protein kinases (MAPKs),12 which can activate
inflammatory processes,13 destabilize mitochondria, and in-
duce cell death.12 A modest activation of PARP can reduce
NADþ levels, as well as the activity of sirtuins (SIRTs), which
play an important role in epigenetic regulation of gene
expression.14 However, overactivation of PARP1 depletes the
cellular pools of NADþ and ATP, eventually leading to necrotic
cell death.13 Consequently, PARP inhibitors may have a
protective role in oxidative stress–related disorders, including
ischemic retinal disease.
It has been reported that neuronal cells of the inner retinal
layers (retinal ganglion and amacrine cells) are the most
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susceptible to hypoxia,4–7 leading to a reduced thickness of the
inner retinal layers.5,8 PARP1 is one of the most important
regulators of cell death processes from a variety of ambient
stimuli.9 In the retina, increased PARP activation leads to optic
nerve transection-induced retinal ganglion cell death15 and is
involved in photoreceptor degeneration in a transgenic mouse
model16 and oxidative stress–induced ganglion cell loss.17 On
the other hand, inhibition of PARP protects against chronic
hypoperfusion-induced neurodegeneration,18 diabetic retinop-
athy,19 and N-methyl-D-aspartate–induced cell death.20
Under stress conditions for the retina such as ischemia–
reperfusion, inflammation can cause injury progression,
although it usually helps in repair. Chronic hypoxia/reoxyge-
nation (H/R) causes excess ROS production and increases
intracellular calcium and mitochondrial damage, leading to
PARP1 activation and further tissue damage. In addition, H/R
activates MAPKs, nuclear factor jB (NFjB), and hypoxia-
inducible factor 1a (HIF1a) that contribute to inflammation
and revascularization, thus causing serious problems in the
retina.21,22
In this study, we used a rat model in which 2 weeks of
retinal hypoxia resulting from systemic hypoxia was estab-
lished, followed by 2 weeks of reoxygenation. This chronic
model provided a better simulation of the conditions of disease
development than those of most previous studies and
represented a reliable method for simulating hypoxia-related
disease processes.23 We analyzed the effect of the PARP
inhibitor olaparib on retinal damage in this model and
described its protective role on retinal structure, cytokine
and chemokine expression, kinase cascades (mammalian target
of rapamycin [mTOR]/phosphoinositide 3-kinase [PI3K]/Akt,
and MAPKs), and activation of related transcription factors,
including NFjB, nuclear factor (erythroid-derived 2)-like 2
(Nrf2), and HIF1a. Our findings indicated that PARP inhibitors
could be potential drug candidates in the therapy of ischemic
retinal damage.
MATERIALS AND METHODS
Animals
Three-month-old male Wistar rats (n ¼ 48) weighing 250 to
300 g were used. The experiment was approved by the
Animal Research Review Committee of the University of Pe´cs
Medical School, Hungary (Permit number: BA02/2000-24/
2011). The animals received care according to the Guide for
the Care and Use of Laboratory Animals published by the
United States National Institute of Health (NIH Publication
number 85-23, revised 1996) and the ARVO Statement for the
Use of Animals in Ophthalmic and Vision Research. Animals
were maintained under a 12-hour light/dark cycle, with free
access to standard rat chow and water.
H/R and Olaparib Treatment
Rats were divided randomly into four groups (n ¼ 12 in each
group). The control group (C) consisted of rats held under
normal pressure (101.3 kPa) and oxygen concentration (21%).
The control þ olaparib group (C þ Olap) contained rats held
under normal pressure (101.3 kPa) and partial oxygen
concentration (21%), receiving olaparib in their drinking water
(estimated 4 mg/kg daily) for 28 days. The H/R group was
composed of rats exposed to 50-kPa air pressure and a 10%
oxygen concentration (equal to that at an altitude of 5000 m
above sea level) for 14 days and then returned to normal
pressure (101.3 kPa) and oxygen concentration (21%) for an
additional 14 days. Finally, the H/R þ olaparib group (H/R þ
Olap) consisted of rats exposed to an air pressure of 50 kPa and
10% oxygen concentration for 14 days and then returned to
normal pressure (101.3 kPa) and oxygen concentration (21%)
for an additional 14 days, with olaparib in their drinking water
(estimated 4 mg/kg daily) throughout the experiment. At the
end of the experiment, rats were anesthetized with 1% sodium
pentobarbital (40 mg/kg) intraperitoneally and euthanized by
cervical dislocation. During the experiment, the animals were
observed twice daily, and all efforts were made to minimize
their suffering. No accidental deaths occurred during the
experiment.
Histologic Analysis
After euthanizing the animals, their eyes (n ¼ 6 per group)
were dissected into 0.1 M PBS and fixed in 4% paraformal-
dehyde (PFA) dissolved in 0.1 M PBS (Sigma-Aldrich Corp.,
Budapest, Hungary). Eyecup tissue was embedded in Durcu-
pan ACM resin (Fluka, Buchs, Switzerland) and then
dissected. Two-micrometer sections were stained with
toluidine blue (Sigma-Aldrich Corp.) and mounted in distyr-
ene-plasticizer-xylene medium (Sigma-Aldrich Corp.). Images
of retinas were captured with a Nikon Eclipse 80i micro-
scope, using the Q-Capture Pro7 program (Nikon, Tokyo,
Japan). Tissue blocks were prepared (four per animals), and
central retinal areas within 1 mm of the optic nerve were
examined (five measurements per tissue block). For the
retinal cross sections from the outer limiting membrane to the
inner limiting membrane (OLM  ILM), measurements were
made of the width of the outer nuclear layer (ONL), the inner
nuclear layer (INL), the outer plexiform layer (OPL), and the
inner plexiform layer. In addition, the cell number per 100-lm
section length in the ganglion cell layer (GCL) was
determined.
Cytokine, Chemokine, and Growth Factor
Measurements
After removal, rat retinas (n ¼ 6 per group) were pooled and
analyzed semiquantitatively using the Proteome Profiler Rat
Cytokine Array Kit, Panel A (R&D Systems, Biomedica, Buda-
pest, Hungary), according to the manufacturer’s protocol.
Samples were homogenized in PBS containing protease
inhibitor cocktail (1:1000; Sigma-Aldrich Corp.), and Triton X-
100 was added to a final concentration of 1%. Detection was
achieved with streptavidin-horseradish peroxidase and a
chemiluminescent detection reagent (Amersham Biosciences,
Budapest, Hungary). Images were captured on X-ray film,
which were scanned and analyzed with Protein Array Analyzer
for ImageJ software (National Institutes of Health, Bethesda,
MD, USA). Assays were repeated three times.
Assessment of Oxidative DNA Damage
Retina samples (n¼ 6 per group) were homogenized in chilled
nuclei lysis solution from the Wizard Genomic DNA Purifica-
tion Kit (Bio-Science Ltd., Budapest, Hungary) and processed
according to the manufacturer’s protocol. Oxidative damage to
the purified genomic DNA samples was assessed using the HT
8-oxo-dG ELISA Kit (Bio-Techne, R&D Systems Ltd., Budapest,
Hungary), according to the manufacturer’s protocol. Assays
were repeated three times.
Immunoblotting
Retina samples (n ¼ 6 per group) were homogenized in ice-
cold homogenization buffer, containing 50 mM Tris, pH 8.0,
and phosphatase and protease inhibitor cocktails (Sigma-
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Aldrich Corp.). Alternatively, nuclear protein extracts were
prepared from retina samples as described previously.24
Precipitated proteins were dissolved in Laemmli sample buffer,
separated on 7%, 10%, or 15% SDS-PAGE gels, and transferred
onto nitrocellulose membranes. Membranes were blocked in
3% nonfat milk for 2 hours, and then they were probed
overnight at 48C with antibodies recognizing the following
antigens (1:500 dilution; Cell Signaling Technology, Danvers,
MA, USA): PARP1, phospho-(p)AktS473, pmTORSer2448, p-
glycogen synthase kinase 3b (pGSK-3b)Ser9, pNFjB p65Ser536,
Nrf2, total Akt, and NFjB p65. Membranes were also probed
with antibodies recognizing the following antigens (1:1000
dilution; GeneTex, Irvine, CA, USA): poly(ADP-ribose) (PAR), p-
extracellular signal-regulated kinase (pERK)1/2Thr202/Tyr204,
pp38 MAPKThr180, pJNK1/2Thr183/Tyr185, acetyl-(Ac)NFjB
p65Lys310, p38 MAPK, JNK1/2, ERK1/2, HIF1a, glyceralde-
hyde-3-phosphate dehydrogenase (GAPDH), and mitogen-
activated protein kinase phosphatase 1 (MKP-1). Appropriate
horseradish peroxidase–conjugated secondary antibodies were
used: goat anti-rabbit antibody (1:3000 dilution; Bio-Rad,
Budapest, Hungary) or rabbit anti-mouse antibody (1:3500
dilution; Sigma-Aldrich Corp.). Protein bands were visualized
with the ECL immunoblotting detection system (Amersham
Biosciences, Piscataway, NJ, USA). Films were scanned, and
pixel densities of the bands were determined using ImageJ
software. Each experiment was repeated four times.
Immunofluorescence
Immunolocalization of nitrotyrosine residues was performed
using standard immunofluorescence techniques. Briefly, eye-
cups (n ¼ 6 per group) were prepared as described above,
fixed in 4% PFA for 2 hours at room temperature, and
cryoprotected in 15% and 30% sucrose solutions at 48C until
the tissues sank. Retinal cryosections were cut to a thickness of
12 lm and stored at 208C until used. Slides were incubated
with anti-nitrotyrosine primary antibody (1:150; Millipore,
Burlington, MA, USA) overnight at room temperature. The
next day, they were incubated for 2 hours with Alexa Fluor 488
secondary fluorescent antibody (1:1000; Invitrogen, Thermo
Fisher Scientific, Waltham, MA, USA). Omission of the primary
antibody from the incubation steps resulted in no labeling
(data not shown). Photographs were taken with an Olympus
Fluorview FV-1000 laser confocal scanning microscope (Olym-
pus, Tokyo, Japan). Images were only adjusted for contrast and
intensity.
Statistical Analysis
Data were expressed as mean 6 SEM. The Kolmogorov-
Smirnov normality test, followed by 2-way ANOVA and Fisher’s
least significant difference (LSD) post hoc analysis, was used to
determine differences (OriginPro, OriginLab, Northampton,
MA, USA). Differences were considered significant at P  0.05.
RESULTS
Effects of Olaparib Treatment on Histologic
Changes of the Retina
Except for a decrease in INL thickness, olaparib treatment did
not cause any morphologic alterations to the retinal layers in
control animals (Figs. 1A, 1B). By contrast, chronic H/R animals
showed signs of severe retinal degeneration compared with
controls, with all layers, except OPL, being significantly
thinner. In addition, several empty cell body–shaped spaces
were seen in the ONL, indicating cell death (Figs. 1A, 1B).
However, the number of cells in the GCL did not change under
H/R and/or olaparib treatment (Figs. 1A, 1B). The reduction of
the individual retinal layers contributed to the severe reduction
of the retinal thickness between the OLM and the ILM (Figs.
1A, 1B). Olaparib treatment ameliorated the aforementioned
effects of chronic H/R and effectively preserved the whole
retinal distance: OLM ILM (Figs. 1A, 1B).
Effects of Olaparib Treatment on PARylation,
PARP1, and Cellular Oxidative Stress Status in the
Retina
To confirm that olaparib could pass through the blood–retina
barrier, we analyzed PARylation and PARP1 levels in the retina
samples. Indeed, we found that the PARP inhibitor olaparib
could effectively decrease PARP1 levels both in the control and
the H/R groups (Figs. 2A, 2B). Furthermore, olaparib treatment
significantly decreased H/R-induced PARylation of the retinal
proteins (Figs. 2A, 2B).
To confirm that the status of cellular oxidative stress had
changed under the different conditions examined, tyrosine
nitrosylation was studied using immunofluorescence. We used
a specific primary antibody against the nitrotyrosine residues,
followed by a fluorescent secondary antibody, on retina
sections. Besides a weak labeling of the photoreceptor layer
under all conditions examined, prominent staining could be
observed in the INL in H/R conditions (Fig. 2C). Olaparib
significantly reduced the nitrotyrosination process when
applied in H/R conditions (Fig. 2C). In addition, to assess
oxidative DNA damage, we determined 8-hydroxy-20-deoxy-
guanosine (8-oxo-dG) levels in the retina samples using a
specific ELISA. H/R was found to increase the oxidative DNA
damage; however, this was reduced close to control levels by
olaparib (Fig. 2D).
Effect of Olaparib Treatment on Cytokine,
Chemokine, and Growth Factor Expression
We measured 29 different cytokines, chemokines, and growth
factors with the Proteome Profiler Rat Cytokine Array Kit,
Panel A (R&D Systems, Minneapolis, MN, USA). Among them,
five showed alterations after H/R and/or olaparib treatment
(Fig. 3A). Olaparib alone did not cause any substantial change
in most of the cytokine levels; however, ciliary neutrotrophic
factor (CNTF), soluble intercellular adhesion molecule-1
(sICAM-1), and reduced thymus chemokine (CXCL7) did
show elevated levels (Fig. 3B). On the other hand, no
significantly increase was observed in levels of CNTF,
fractalkine (CX3CL1), sICAM-1, CXCL7, and VEGF in retinas
subjected to H/R conditions compared with the control group
(Fig. 3B). Olaparib treatment attenuated the activation of
CNTF, fractalkine, sICAM-1, and VEGF induced by H/R (Fig.
3B).
Effects of Olaparib Treatment on mTOR/PI3K/Akt/
and MAPK Pathways in H/R-Induced Retinal Injury
Olaparib treatment elevated the phosphorylation (activation)
of mTORSer2448 (Figs. 4A, 4B). However, H/R increased mTOR
phosphorylation to a much higher extent than olaparib and
was diminished by the addition of olaparib (Figs. 4A, 4B).
Phosphorylation (activation) of Akt and phosphorylation
(inactivation) of its downstream target GSK-3b were signifi-
cantly elevated following olaparib treatment in control retinas
(Figs. 4A, 4B). H/R also enhanced phosphorylation of these
proteins compared with the control, although in a much lower
extent than olaparib. However, H/R þ Olap treatment caused
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an increase in the phosphorylation of Akt and GSK-3b that
exceeded that of CþOlap (Figs. 4A, 4B). These patterns were
consistent with the notion that Akt-mediated phosphorylation
and inactivation of GSK-3b could be protective in retinal
diseases.25
We also examined the expression level of MAPKs under our
experimental conditions (Fig. 5A). ERK1/2 phosphorylation
was increased after H/R and remained elevated after H/R þ
Olap treatment (Figs. 5A, 5B). Olaparib treatment did not affect
either the phosphorylation of p38 MAPK or JNK. By contrast,
H/R increased pp38 MAPK and pJNK levels that were
significantly diminished by olaparib (Figs. 5A, 5B). Because
MKP-1 was a negative regulator of p38 MAPK and JNK,26 we
analyzed its expression. H/R had no effect on MKP-1 levels;
however, olaparib treatment increase MKP-1 levels in the
control, as well as in the H/R groups (Figs. 5A, 5B).
FIGURE 1. Effect of olaparib treatment on histologic changes of the retina induced by H/R. (A) Light microscopic images of retinal cross sections
stained with toluidine blue. Representative images are presented (n¼ 6 per group). (B) Quantitative analysis of the thickness of retinal layers: IPL,
INL, ONL, and OPL, cross section of the retina from the outer limiting membrane to the inner limiting membrane (OLM–ILM), and the number of
cells/100 lm in the GCL. Data are presented as mean 6 SEM of four independent measurements. *P  0.05 compared with control group; #P  0.05
compared with H/R group (ANOVA with Fisher’s LSD post hoc analysis).
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FIGURE 2. Effect of olaparib treatment on PARylation, PARP1, nitrotyrosine, and 8-hydroxy-20-deoxyguanosine levels in H/R-induced retinal injury.
(A) Expression of PAR and PARP1 determined by immunoblotting using protein-specific primary antibodies. (B) Densitometric analysis of
immunoblots is presented in bar diagrams. GAPDH is used as an internal control. Data are presented as mean 6 SEM of four independent
measurements. *P  0.05 compared with control group; #P  0.05 compared with H/R group (ANOVA with Fisher’s LSD post hoc analysis). (C)
Cryosections stained with anti-nitrotyrosine antibody. A light background staining in the ONL is characteristic of all four experimental conditions.
Elective staining of the INL can be seen for H/R conditions. Several cell bodies of presumed amacrine cells (arrows) are particularly strongly labeled.
Olaparib reduces H/R-induced nitrosylation. Representative images are presented (n¼6 per group). (D) Oxidative DNA damage assessed with an 8-
oxo-dG ELISA Kit. The results are presented as a bar diagram, mean 6 SEM of three parallel measurements of six independent samples in each
groups. *P  0.05 compared with control group; #P  0.05 compared with H/R group (ANOVA with Fisher’s LSD post hoc analysis).
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FIGURE 3. Effect of olaparib treatment on cytokine, chemokine, and growth factor expression in H/R-induced retinal injury. (A) Nitrocellulose-
based rat cytokine array assay performed on retina homogenates (n¼6 per group). (B) Quantitative analysis of CNTF, CX3CL1/fractalkine, sICAM-1,
CXCL7/thymus chemokine, and VEGF expression. Data are presented as mean 6 SEM of three independent experiments. *P  0.05 compared with
control group; #P  0.05 compared with H/R group (ANOVA with Fisher’s LSD post hoc analysis).
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FIGURE 4. Effect of olaparib treatment on the PI3K/Akt/mTOR pathway in H/R-induced retinal injury. (A) Expression and phosphorylation of
mTOR, Akt, and GSK-3b determined by immunoblotting using phosphorylation-specific primary antibodies. Representative images are presented (n
¼ 6 per group). (B) Densitometric analysis of immunoblots is presented in bar diagrams. Bands were normalized to the appropriate Akt and GSK-3b
bands. Data are presented as mean 6 SEM of three independent experiments. *P  0.05 compared with control group; #P  0.05 compared with H/
R group (ANOVA with Fisher’s LSD post hoc analysis).
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FIGURE 5. Effect of olaparib treatment on the MAPK pathways in H/R-induced retinal injury. (A) Expression and phosphorylation of p38 MAPK,
JNK, and ERK1/2, as well as expression of MKP-1, determined by immunoblotting using phosphorylation-specific primary antibodies.
Representative images are presented (n ¼ 6 per group). (B) Densitometric analysis of immunoblots is presented in bar diagrams. Bands are
normalized to the appropriate p38 MAPK, JNK1/2, and ERK1/2 bands. GAPDH is used as an internal control. Data are presented as mean 6 SEM of
three independent experiments. *P  0.05 compared with control group; #P  0.05 compared with H/R group (ANOVA with Fisher’s LSD post hoc
analysis).
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Effect of Olaparib Treatment on HIF1a, Nrf2, and
NFjB Activation, in Addition to Phosphorylation
and Acetylation of NFjB p65 in H/R-Induced
Retinal Injury
The abovementioned signaling pathways regulated the expres-
sion of numerous transcription factors, among which, HIF1a,
Nrf2, and NFjB levels were assessed. HIF1a levels were
significantly increased after olaparib treatment (Figs. 6A, 6B).
Nevertheless, the increase was more pronounced in the H/R
group and was appreciably attenuated by olaparib (Figs. 6A,
6B). Olaparib-treatment (C þ Olap) and H/R treatment alone
did not increase the level of Nrf2 levels significantly; however,
they rose dramatically and significantly in H/R þ Olap retinas
(Figs. 6A, 6B). Even so, the treatments did not affect steady-
state NFjB levels (Fig. 6A). However, nuclear translocation
rather than changes in steady-state levels would indicate
activation of Nrf2 and NFjB. Therefore, we assessed nuclear
translocation of these transcription factors from nuclear
protein extracts of retinas by immunoblotting. C þ Olap and
H/R treatments, and H/RþOlap treatment to a greater extent
showed an increase in nuclear translocation of Nrf2 (Figs. 6A,
6B). By contrast, olaparib reduced, whereas H/R elevated,
NFjB nuclear translocation, and the latter effect was abolished
by olaparib (Figs. 6A, 6B).
It was well established that NFjB activation was regulated
by various kinase signaling pathways, including the above-
mentioned PI3K–Akt and MAPK pathways.27 We observed
increased phosphorylation, thereby activation of NFjB
p65Ser536 in H/R retinas, which was diminished by olaparib
treatment (Figs. 6A, 6B). These data showed that the PARP
inhibitor olaparib could regulate NFjB activation by regulating
MAPKs. NFjB p65Lys310 acetylation, and thereby activation,
was also determined. Acetylated NFjB p65Lys310 levels were
significantly elevated under H/R conditions, whereas olaparib
treatment decreased acetylation in H/R-treated retinas (Figs.
6A, 6B), thereby reducing NFjB activation as previously
suggested.28
DISCUSSION
ROS overproduction during ischemia–reperfusion can cause
DNA damage that triggers PARP1 activation, which is one of
the most important regulators in cell death processes for
numerous diseases.29–31 Elevated PARP activation has been
detected in several types of retinal degeneration, such as
diabetic retinopathy, retinitis pigmentosa, and ischemia–
reperfusion–induced cell death in the retina.18,19,32–37 Recent
data indicate that PARP inhibitors provide therapeutic benefits
in cancer treatment,38,39 and PARP has been proposed as a
potential target in nononcologic diseases.40 Inhibition of PARP
protected the retina in the bilateral common carotid artery
occlusion (BCCAO) model,18,41 as well as in the hypoxia–
reperfusion model elicited by raising IOP.42,43 In the BCCAO
model, PARP inhibition activated one of the most important
cytoprotective pathways, the PI3K–Akt, and suppressed the
p38 MAPK and JNK pathways.18
In this study, we analyzed kinase signaling in the retina
under chronic H/R and found that a PARP inhibitor induced the
activation of Akt, thereby inactivating GSK-3b,18 processes that
may play a protective role in retinal H/R. These results are
consistent with previous findings that inhibition of GSK-3b has
protective effects in the retina,44 and Akt activation is
cytoprotective in oxidative stress situations.45,46 In oxidative
stress, PARP inhibition is reported to downregulate JNK and
p38 MAPKs12,26 that can also have a protective role in the
retina. JNK initiates mitochondrial fission and a variety of
programmed cell death mechanisms,47,48 whereas activation of
p38 MAPK predominantly contributes to inflammation.49
Another potential effect of PARP inhibitors is in anti-
inflammation.50 Besides elevating ROS, H/R increases cyto-
kine/chemokine levels.51,52 As such, we used a rat cytokine
array to detect H/R-induced changes and the effect of olaparib
treatment on them. Of the 29 cytokines, chemokines, and
growth factors that were examined, 5 showed marked changes
in our experiment, namely CNTF, fractalkine, sICAM-1, CXCL7,
and VEGF. CNTF, a member of the IL6 family, is one of the most
studied neurotrophic agents in retinal diseases.53 Preclinical
studies in more than 12 animal models from four different
species provide strong support for the neuroprotective effect
of CNTF on photoreceptors and ganglion cells in the
retina.54–57 Intravitreal injections of recombinant CNTF have
also been shown to promote capillary regrowth and attenuate
preretinal neovascularization in a mouse model of oxygen-
induced retinopathy.58 Normal neurons in the central nervous
system, as well as in the retina, constitutively express
fractalkine.59 Disruption of fractalkine signaling influences
microglial physiology in disease conditions.60 VEGF, as an
important angiogenic factor, plays a role in several retinopa-
thies, such as retinopathy of prematurity and diabetic
retinopathy. However, it could also have a neuroprotective
function. In retinal ischemia, the influence of its expression
depends on timing, localization, and reperfusion.61,62 In the
current study, olaparib treatment significantly reduced VEGF
levels in hypoxic retina, which could be related to PARP
inhibitor-induced reduction of HIF1a and NFjB levels (Fig.
6).63
Most of the aforementioned cytokine and chemokine
expressions were regulated by NFjB, which was reported to
activate a number of cytokine and growth factor genes
associated with ischemia–reperfusion injury in the retina.64,65
NFjB is retained in the cytoplasm in an inactive form by its
inhibitor, IjB, which is subjected to phosphorylation-mediated
degradation. A number of signaling kinases, including MAPKs,
phosphorylate and thereby activate IjB kinase. After removal
of IjB, a nuclear localization signal on NFjB becomes
unmasked, and the transcription factor translocates to the
nucleus, where it is activated by phosphorylation and
acetylation to stimulate NFjB-dependent gene expression.66
H/R activates MAPKs, including p38 MAPK, which is respon-
sible for the phosphorylation of p65Ser536. Therefore, the MKP-
1 expression inducing effect of PARP1 inhibition26 explains
how olaparib can reduce phosphorylation of p65Ser536, thereby
attenuating inflammation during H/R. We found that acute H/R
activated the acetylation of subunit p65Lys310 of NFjB,
contributing to the activation of this transcription factor (Fig.
6). It is not surprising that H/R increases p65 acetylation
because SIRT enzymes (NADþ-dependent deacetylases) are
responsible for the deacetylation of p65. Upon activation,
PARP1 consumes NADþ, thereby reducing SIRT activity (Fig. 7).
Inhibition of PARP maintains NADþ levels and consequently
SIRT activity, resulting eventually in significantly reduced
p65Lys310 acetylation (Figs. 6, 7).
As expected, H/R caused considerable cell death, as was
revealed by a decrease in the thickness of all retinal layers but
OPL and the presence of observable lesions (Fig. 1). It also
induced significant protein (Fig. 2C) and DNA damage (Fig.
2D). All these effects were significantly attenuated by olaparib
(Figs. 1, 2). In addition to the aforementioned protective
effects, olaparib treatment dramatically increased Nrf2 levels
(Fig. 6), the main transcription factor activating the expression
of antioxidant enzymes. This was the first report indicating that
PARP inhibition could contribute to better protection against
H/R-related oxidative stress, possibly by elevating Nrf2.
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FIGURE 6. Effect of olaparib treatment on HIF1a and Nrf2 expression and on NFjB p65 phosphorylation and acetylation in H/R-induced retinal
injury. (A) Expression of HIF1a, Nrf2, and NFjB p65, as well as the phosphorylation and acetylation of NFjB p65 determined by immunoblotting
using phosphorylation- and acetylation-specific primary antibodies. Representative images are presented (n ¼ 6 per group). (B) Densitometric
analysis of immunoblots is presented in bar diagrams. Bands are normalized to the appropriate GAPDH and NFjB internal control. Data are
presented as mean 6 SEM of three independent experiments. *P  0.05 compared with control group; #P  0.05 compared with H/R group
(ANOVA with Fisher’s LSD post hoc analysis).
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In conclusion, we demonstrated the possible protective
effects of the PARP inhibitor olaparib in a chronic retina H/R
model, characterized by histologic changes (Fig. 1), cytokine
expression patterns (Fig. 3), signaling cascades (Figs. 4, 5), and
transcription factor activation (Fig. 6). These findings provided
further insight into the neuroprotective mechanism of olaparib
in a systemic H/R model. They also showed that olaparib
treatment ameliorated ischemic retinal injury involving anti-
inflammatory actions by diminishing NFjB p65 phosphoryla-
tion (Ser 536) and thereby activation most probably via the
PARP1–MKP-1–p38 MAPK–NFjB p65 pathway, and by pro-
moting deacetylation (Lys310), thereby inactivation of NFjB
p65, possibly via the PARP1–NADþ–SIRT1 pathway (Fig. 7). In
addition, we found that the PI3K–Akt pathway and JNK
downregulation via activation of MKP-1 expression might also
have contributed to a protective effect of the PARP inhibitor
against oxidative stress–induced retinal cell death. Taken
together, these data suggest a therapeutic potential for olaparib
or other nontoxic PARP inhibitors in retinal disease.
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